Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
cancer immunotherapy
4
×
clinical trials
4
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
4
×
national blog main
national top stories
new york blog main
new york top stories
novartis
4
×
raleigh-durham blog main
raleigh-durham top stories
4
×
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
boston top stories
fda
gilead sciences
glaxosmithkline
immunotherapy
nonalcoholic steatohepatitis
startups
akcea therapeutics
biogen
cancer
What
roundup
bio
nash
news
abbvie’s
according
acquisitions
ahead
akcea
announced
approval
biofourmis
biogen’s
biopharmaceutical
biotech
bucks
cancer
cases
celebrate
centers
ceo
chance
cigarettes
collabs
companies
control
convo
corner
covid
daniel
day
days
deal
deaths
disease
drug
earlier
electronic
failures
forward
Language
unset
Current search:
novartis
×
national
×
" raleigh-durham top stories "
×
" clinical trials "
×
" cancer immunotherapy "
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More